Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P930021/S034

Straumann Emdogain

The Straumann Company · Decision date Sep 5, 2025

FDA DECISIONP930021/S034

What did the FDA decide?

FDA records P930021/S034 as a supplement to PMA P930021, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Sep 5, 2025.

FDA approval order statement

implementation of new Blue zone cleanroom area (ISO 7/8)
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Dental
Decision date
Sep 5, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P930021/S034
Regulatory pathway
PMA supplement
Product code
NQA
Decision code
OK30
Decision date
Sep 5, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Biologic material, dental.

Product code
NQA
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P930021/S034 received

    Application receipt date recorded by FDA.

  2. P930021/S034 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P930021. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

The Straumann Company

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
60 Minuteman Rd., Andover, MA, 01810

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records